XARELTO
PeakNDAORALTABLET
Approved
Nov 2011
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2053
Data completeness
5/8 — Partial
IRA Negotiated
XARELTO by Johnson & Johnson is fxa. Approved for deep vein thrombosis (dvt), pulmonary embolism (pe), which may lead to pe in adult patients undergoing knee and 17 more indications. First approved in 2011.
Drug data last refreshed 2d ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XARELTO (rivaroxaban) is an oral anticoagulant small molecule approved in 2011 for prevention and treatment of thromboembolic disorders. It is a Factor Xa inhibitor used across multiple indications including atrial fibrillation, venous thromboembolism, and acute coronary syndrome. Currently in peak lifecycle stage with sustained market demand.
$6.3BPart D
PeakStable
Peak lifecycle status with $6.3B in annual spending indicates mature, stable commercial infrastructure; significant IRA price negotiation in 2026 will require defensive strategy and cost management focus.
Mechanism of Action
FXa. It does not require a cofactor (such as Anti-thrombin III) for activity. Rivaroxaban inhibits free FXa and prothrombinase activity. Rivaroxaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, rivaroxaban…
Indications (20)
Worked on XARELTO at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.